Hyperparathyroidism News and Research

RSS

Hyperparathyroidism is a condition in which the parathyroid gland (one of four pea-sized organs found on the thyroid) makes too much parathyroid hormone. This causes a loss of calcium from the bones and an increased level of calcium in the blood. Symptoms include bone pain and kidney problems.

In most cases doctors don't know the cause. The vast majority of cases occur in people with no family history of the disorder. Only about 5 percent of cases can be linked to an inherited problem. Familial multiple endocrine neoplasia type 1 is a rare, inherited syndrome that affects the parathyroids as well as the pancreas and the pituitary gland. Another rare genetic disorder, familial hypocalciuric hypercalcemia, is sometimes confused with typical hyperparathyroidism. Each accounts for about 2 percent of primary hyperparathyroidism cases.

In the United States, about 100,000 people develop the disorder each year. Women outnumber men two to one, and risk increases with age. In women 60 years and older, two out of 1,000 will develop hyperparathyroidism each year.

Keryx announces positive top-line results from Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc. today announced positive top-line results from the Phase 3 short-term efficacy study component of its Phase 3 registration program of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

30 Nov 2010

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals reported today the randomization of the last patient in its short-term study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

26 Oct 2010

Vitamin D deficiency may impact orthopaedic procedure outcomes

Forty-three percent of patients scheduled to undergo orthopaedic surgery have insufficient levels of vitamin D and two out of five of those patients had levels low enough to place them at risk for metabolic bone disease, according to a study published this month in the October 6th issue of the Journal of Bone and Joint Surgery (JBJS).

7 Oct 2010

Keryx commences Zerenex Phase 3 study for hyperphosphatemia in patients with ESRD on dialysis

Keryx Biopharmaceuticals, Inc. announced today the initiation of the long-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.

29 Sep 2010

KAI Pharmaceuticals enrolls patients in Phase 1b study of KAI-4169 for treatment of SHPT

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 1b study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism, which is a frequent and serious complication of end-stage renal disease.

27 Sep 2010

Chemical compound provides new angle for developing drugs to treat seizures: Study

A chemical compound that boosts the action of a molecule normally produced in the brain may provide the starting point for a new line of therapies for the treatment of epileptic seizures, according to a new study by scientists at The Scripps Research Institute.

30 Jul 2010

KAI Pharmaceuticals completes enrollment in Phase 1 study of KAI-4169 for SHPT

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has completed enrollment in a Phase 1 study of KAI-4169, a novel pharmaceutical agent for the treatment of secondary hyperparathyroidism, which is a frequent complication of end stage renal disease.

20 Jul 2010

ADVANCE study provides new insights into the management of SHPT in CKD patients

Results from the ADVANCE study presented in a late breaking clinical trial session at the ERA-EDTA 2010 Congress provide new insights into the management of secondary hyperparathyroidism in chronic kidney disease patients. ADVANCE (A randomiseD VAscular calcificatioN study to evaluate the effects of CinacalcEt) is a randomised, controlled open label study to evaluate the effects of treatment with Mimpara (cinacalcet) plus low-dose vitamin D, compared to flexible doses of vitamin D alone, on the progression of vascular and valvular calcification in dialysis patients with SHPT.

28 Jun 2010

Molecular imaging fusion with CT anatomy results in precise localization of parathyroid lesions: Research

SNM's 2010 Image of the Year illustrates the potential of hybrid molecular imaging to provide precise information about the location and function of a condition known as "hyperparathyroidism." Researchers selected this image from more than 1,500 studies presented over the course of four days during SNM's 57th Annual Meeting in Salt Lake City.

16 Jun 2010

Newly published research examines association between CKD and CYP24

Cytochroma today announced the publication of new data from studies in a preclinical model indicating that chronic kidney disease is associated with markedly increased expression of the vitamin D catabolic enzyme, CYP24, which contributes to vitamin D insufficiency and resistance to vitamin D therapy. Parallel analysis of kidney biopsies obtained from CKD patients confirmed abnormal CYP24 expression in human disease as well.

16 Jun 2010

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.

25 May 2010

Cytochroma reports positive Phase 1/2 results for CTAP101 Capsules in non-dialysis CKD patients

Cytochroma today announced positive Phase 1/2 results for CTAP101 Capsules, a product being developed to treat secondary hyperparathyroidism (SHPT) associated with vitamin D insufficiency in non-dialysis chronic kidney disease (CKD) patients. The study demonstrated that a single dose of CTAP101 Capsules was safe, effective and well tolerated.

25 May 2010

Vitamin D plays much wider role in people's life

Vitamin D is the sunshine vitamin - we make it when our skin is exposed to UV rays. In a perfect world everyone would eat fresh, organic foods, get outside, and enjoy a little sunshine all year round. But with today's busy lifestyles and concerns about skin cancer many people are vitamin D deficient and don't know it.

21 May 2010

FDA grants tentative approval for Teva's Cinacalcet HCl Tablets ANDA

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Cinacalcet HCl Tablets 30, 60 & 90 mg.

15 May 2010

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

Keryx Biopharmaceuticals, Inc. announced today the initiation of its short-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

6 May 2010

Cytochroma reports positive results from Phase I trial for CTAP201 Injection in hemodialysis patients

Cytochroma today announced positive Phase I results for CTAP201 Injection, a product being developed to treat secondary hyperparathyroidism in hemodialysis patients. The study demonstrated that single intravenous doses of 1 and 3 mcg of CTAP201 were safe and well tolerated. It also identified a starting dose of 2 mcg for subsequent pivotal trials intended to establish the product's safety and efficacy in the targeted population.

6 May 2010

NPS Pharmaceuticals sells royalty rights from sales of REGPARA to DRI Capital's fund

NPS Pharmaceuticals, Inc. today announced the sale of its royalty rights from sales of REGPARA® (cinacalcet HCl) to a fund managed by DRI Capital, Inc., (Fund) for $38.4 million. Royalties in excess of cumulative royalties of $96 million or 2.5 times the upfront purchase price have been retained by NPS.

3 Mar 2010

Formatech donates $308K in aseptic liquid fill and finish manufacturing services

Formatech continues its pledge to give back and make a difference in the biotechnology and pharmaceutical community with its Fillanthropy Program. Since the program’s inception, Formatech has donated $308K in aseptic liquid fill and finish manufacturing services to companies developing new drug therapies.

28 Jan 2010

Keryx Biopharmaceuticals reaches SPA agreement for Phase 3 clinical program for Zerenex

Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 clinical program for Zerenex(TM) (ferric citrate), its iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD).

6 Jan 2010

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009